• Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) specializes in the use of ultra-high pressure technologies to innovate unexpected and potent solutions for a wide variety of industries, including biomarker and target discovery, forensics, counter-bioterror applications, improved quality and economics for biopharmaceuticals, and safer, more potent and more cost-effective, storage, dosing and absorption of nutrients, nutraceuticals, cosmeceuticals, agrochemicals for plants, and more
• Pressure BioSciences recently announced the development of extraordinarily effective dosing and delivery in uniform nanoemulsions of 30 to 60 nm droplets for the powerful antioxidant astaxanthin (“AsX”), and suitable for many other prospective nutraceuticals
• PBIO’s technology for nanoemulsions commands extremely high commercial appeal because of its ability to dramatically improve the entire sensory profile of many retail products, while simultaneously improving the economics for producers and/or consumers, and making medicines and nutraceuticals safer, more easily absorbed, and more bioavailable within targeted humans, animals and plants
• Their breakthrough achievement in AsX nanoemulsions is simply the demonstration gateway to the potential production of an enormous range of more bioavailable, higher quality fat-soluble vitamins, nutraceuticals and dietary supplements
• Preorders for its first dozen commercial nanoemulsion production systems are converting into PBIO’s powerful new leasing and royalty driven business model, with initial, solid incremental revenue expected in early 2022

The development of the oil-soluble antioxidant astaxanthin as an extremely fine and uniform nanoemulsion that easily disperses and effectively dissolves into water with intrinsic stability, was announced July 1, and launches a revolutionary new growth phase for life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) and its trademarked Ultra Shear Technology(TM) (“UST”) platform. Pressure BioSciences (also known as PBI) has developed its UST platform to apply ultra high pressure and intense shearing forces for the innovative production of a unique class of high-quality nanoemulsions that offer enormous new benefits in a wide variety of industries, including the nutraceuticals market, which is expected to powerfully leverage the benefit of the astaxanthin nanoemulsions development, into a plethora of other newly differentiated nutraceutical products. Astaxanthin, or AsX, is renowned as an antioxidant 6000 times more powerful than vitamin C that has been shown clinically to enhance the human body’s natural immune response, improve muscle endurance in exercise, support cardiovascular, brain and eye health, protect skin against UV damage, and beneficially modify cell signaling pathways that promote cancer cell death, according to Pressure BioSciences’ news release (https://ibn.fm/pKhEn). Because AsX is essentially water-insoluble, the body’s ability to absorb it rather than simply passing it through to excretion has been measured at typically less than 10 percent of the amount of ingested or topically applied compound. The nanoemulsion developed through the UST pressure and shearing IP has the potential to make AsX more easily and fully absorbed and bioavailable, and thus more effective with lower dosing and improved economics for the producer and/or the consumer.  Similar benefits for other carotenoids and a wide range of fat-soluble vitamins, nutraceuticals, dietary supplements are anticipated, and will extend into agrochemicals, cosmeceuticals and personal care products, and other industries. “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter” PBI Senior Research Scientist Gary B. Smejkal stated in the news release. “The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published.” Pressure BioSciences anticipates the use of its technology will make it possible for nutraceutical companies to exercise greater control over their dosing and find ways to lower their costs, which may in turn lower the costs for consumers. The pressure-shearing process also reduces the need for large amounts of added chemicals used currently in chemically produced nanoemulsions. “The global astaxanthin market size was estimated at USD 1.0 billion in 2019,” PBI President and CEO Richard T. Schumacher stated. “PBI is laser-focused on exploring the opportunities for our UST platform to profoundly alter the effectiveness and competitiveness of a great number of lucrative nutraceutical products. We have already begun discussions with prospective partners worldwide who are interested in using UST for production and commercialization of astaxanthin and other nutraceutical nanoemulsions.” The company has received pre-orders for 12 BaroShear K45 systems, the company’s first commercial application of its UST-based processing system, and expects to be able to fulfill the orders beginning late this year through a lease/royalty business model, which it expects to generate up to $3 million in incremental revenue in late 2021 and early 2022 (https://ibn.fm/AXJlp). Pressure BioSciences boasts an intellectual property portfolio already including more than 25 patents worldwide and is advancing rapidly towards inflections into significantly increased revenues and profitability. In addition to the nutraceuticals nanoemulsions market, the company’s primary focus includes pressure-based technology development of products for biomarker and target discovery, improved soil and plant biology, forensics, counter-bioterror applications, and improved quality and economics for biopharmaceuticals. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• SGTM transforms storm, hurricane waste into environmentally beneficial products that enhance, fortify the earth
• Company on solid growth trajectory with string of lucrative contracts awarded in recent months
• Clients include municipal governments, large commercial retailers including The Kroger Co, Circle K, Menards Inc. & Old Castle Lawn & Garden
• 2020 was record-breaking year, Q1-2021 results include QoQ increases of 16.7% in revenue and 8.6% in gross profit

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is on a growth trajectory with a lucrative string of large commercial contracts, a rock-solid growth strategy, and its unique business model rooted in sustainability (https://ibn.fm/wGE5L). SGTM’s synergistic business activities benefit the earth by diverting waste that otherwise would have burdened municipal landfills and transforming it into products that fortify and enhance the earth. Through its subsidiary National Storm Recovery LLC, SGTM is contracted to cut, haul and remove large volumes of clean wood debris that is then processed by Mulch Manufacturing Inc. – another SGTM wholly owned subsidiary – into organic gardening mulch and playground surfacing material. Besides allowing the company to eliminate disposal costs, this synergistic business model enables SGTM to receive mulch feedstock of high quality at a much lower net cost for maximum profits. “Getting paid for your feedstock in the mulch business is a recipe for success and great profit margins,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/FniIJ). “Storm recovery is a multibillion-dollar business, and we are prepared to help in any cleanup process.” SGTM broke records in 2020 with year-over-year increases of 794% in revenue and 4,817% in gross profit (https://ibn.fm/gLvEO), and the trend has continued for Q1-2021 with quarter-over-quarter increases of 16.7% in revenue and 8.6% in gross profit (https://ibn.fm/M6KvN). The company’s business model – unique to the industry – allows it to profit in two ways: first by offering paid services that enable it to acquire its feedstock and second by processing and selling the transformed products to large-scale commercial retailers such as The Kroger Co, Circle K, Menards Inc. & Old Castle Lawn & Garden. “This business combination has created an industry powerhouse, and with our combined strengths puts us in an ideal position to increase our sales and resulting margins as our combined operations benefit from the resulting vertical integration and economies of scale,” said Mulch Manufacturing CEO Ralph Spencer (https://ibn.fm/BlllT). SGTM’s centralized operations are based in Jacksonville, Florida across 26 acres with ample room to expand. With over 40 years of next-level experience with mulch manufacturing and tree management, SGTM’s leadership is committed to sustainably growing the company through a multi-pronged strategy that puts stewardship of the environment at the core of its mission. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/A0LxQ. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• The direct-sales space reported $40.1 billion in retail sales last year, an increase of 13.9% from 2019
• Successful direct-sales companies adapt quickly to a world with changing needs
• SHRG is working on multiple programs, expansion plans that will be unprecedented in the sector

The United States saw record high sales, sellers and customers in the direct-sales sector in 2020, according to the industry’s leading national trade association (https://ibn.fm/aymKA). That news bodes well for Sharing Services Global (OTCQB: SHRG), a publicly traded company specializing in the direct-sales sector. In its annual Growth & Outlook Study, the U.S. Direct Selling Association (“DSA”) reported exciting numbers for companies — and people — involved in the direct-sales space. According to the DSA, the direct-selling channel generated $40.1 billion in retail sales in 2020, an increase of 13.9% from 2019; the number of individuals selling products or services through a direct-selling business model also increased more than 13%, with 7.7 million U.S. entrepreneurs involved on either a full-time or part-time basis; and demand for products and services offered in the direct-selling sector grew as well, with 41.6 million preferred customers and discount buyers purchasing through the direct-sales channel. “America is forever changing, no more so than during the last year,” said DSA president Joseph N. Mariano. “Direct sellers have proven themselves time and again to be nimble microentrepreneurs, willing and able to serve their customers and communities within a changing environment. . . . Direct-selling companies also adapted quickly to a world with changing needs by empowering their independent sellers with the tools to serve their customers and fellow sellers — innovative technology, updated health and safety policies, and second-to-none business support.” Sharing Services Global can count itself among the savvy direct-sales companies that are nimble and quick to adapt to changing market needs. Earlier this year, the company announced a new brand identity for its two wholly owned subsidiaries: Elevacity Holdings LLC and Elevacity U.S. LLC, leading producers and distributors of nootropic, functional beverage products with a focus on health and wellness (https://ibn.fm/bPs2E). The new identity, branded The Happy Co., includes a complete redesign of both the consumer-facing website where The Happy Co. customers purchase products and the business-focused website that showcases the overarching opportunity. A few weeks later, the company announced its newest subsidiary, a travel company called Hapi Travel Destinations (https://ibn.fm/V3ZDJ). These announcements were made alongside news that SHRG was planning to expand into both Asia and Europe. The company is focused on establishing strategic plans to make the most of the opportunities provided in the growing direct-sales industry. “This is a very exciting time in the company, as we are working on multiple programs and expansion plans that will be unprecedented in this sector,” said Bo Short, CEO of Elevacity Holdings LLC and Elevacity International Holdings LLC. “I have been in direct selling for many years and have never seen an executive management team with such a long-term vision to reshape this industry and really serve its brand partners in this fashion. I’m excited and honored to be part of these new initiatives.” For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• HempFusion Wellness closed the acquisition of Sagely Naturals, a women-centric CBD company, for an initial consideration of US$25 million in cash and stock payments
• The acquisition is expected to benefit both parties in various ways, including by increasing HempFusion’s revenue and providing access to Sagely’s extensive distribution footprint
• On its part, Sagely will benefit from HempFusion’s regulatory compliance, which will help in the introduction of ingestible CBD products
• HempFusion is looking forward to driving shareholder value through continued growth both domestically and internationally with its expanding family of brands

In fulfillment of a merger agreement announced in late May, Denver-based leading health and wellness company HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 800) completed the acquisition of premier women-centric CBD brand Sagely Enterprises Inc. (“Sagely Naturals”) on July 7 (https://ibn.fm/qIzoy). The purchase, which made Sagely Naturals a wholly owned subsidiary of HempFusion Wellness, is expected to benefit both parties. Boasting an extensive retail distribution footprint of 14,000+ stores in the United States, Sagely Naturals is the third most successful brand, leading CBD topicals brand, and largest women-founded CBD company in the industry. This market position is reflected in its financials for the fiscal year 2020, in which it reported net revenue of over $4.19 million. The now wholly owned subsidiary provides HempFusion with immediate distribution to up to 14,000 additional stores as well as a significant increase in revenue. In fact, when combined with the closing of APCNA Holdings LLC’s (“Apothecanna”) purchase agreement, announced May 17, HempFusion’s 2020 revenue will more than triple. Both acquisitions further offer the opportunity to expand this revenue well into the future. In an interview with Proactive (https://ibn.fm/xfGSM), HempFusion CEO Jason Mitchell, N.D., noted that while Sagely Naturals does not offer ingestible CBD products at the moment, HempFusion’s focus on being regulatorily compliant will allow it to install a completely new ingestible program for them. This will provide an opportunity to introduce ingestible CBD products in up to 14,000 stores. “So, we are going to give them near-immediate expansion into new products they haven’t had previously,” said Mitchell. HempFusion’s significant investment into regulatory compliance will help solidify Sagely Natural’s leadership position in the CBD industry. HempFusion has also included Sagely Naturals on its Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency to aid in future expansion into Europe. Additionally, as both companies have complementary product offerings that do not directly compete, the acquisition offers substantial cross-platform opportunities through each of their respective distribution channels. “Integration has been well underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” stated Mitchell in a press release. HempFusion closed the acquisition for an initial consideration of US$25 million, of which $2 million was paid in cash (subject to adjustment for Sagely Naturals’ cash and working capital), and the balance was satisfied by the issuance of more than 22.5 million common HempFusion shares. You can find a comprehensive description of the terms of the acquisition in the press release. In the Proactive interview, Mitchell held that M&A remains a vital part of the company’s future. Thus, the recent acquisition of Sagely Naturals “is certainly not going to be our last.” For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

Date: July 21-23, 2021  Virtual Event Companies and professionals from the biocompatibility, toxicology, materials engineering, and related medical fields are invited to attend the Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference being held on July 21-23, 2021. Industry leaders and regulatory authorities will share presentations discussing compliant design and commercialization evaluation processes for medical device professionals to develop safe testing strategies. This online streaming conference is a great opportunity for you to meet and collaborate with industry professionals to ensure your products meet biological safety requirements as per the global safety standards. The event will be hosted on the dynamic Q1 Productions virtual platform that customizes the user experience by connecting attendees with their peers. Attendees will get answers to their queries while the dynamic formats ensure that participants enjoy the virtual experience. Industry leaders attending the conference will discuss safety measures and safety standards to meet the design requirements for the commercial market. The event is sponsored by WuXi AppTec Medical Device Testing, a world-class solution provider offering integrated, testing solutions that enable clients to develop strategies and safe life-changing healthcare solutions for patients and caregivers. The conference media partner is BioMedWire (“BMW”), a technology-driven communications platform. Important points to be covered at the Conference:

• Designing proper biological evaluation plans in a risk management process
• Discussion on the criteria, selection, and common measures for risk-based biological evaluation planning
• Ways to refine E&L Testing performance and efficiency
• Overcoming biocompatibility and toxicology challenges of the world markets
• Partnering with lab-testing services for better navigation, communication and to overcome the lack of uniformity
• Defining testing criteria for ethylene oxide residual testing
• Optimizing biocompatibility analysis in response to manufacturing alterations

The 2^nd Annual Medical Device Biocompatibility & Toxicology Risk assessment Conference offers insights and valuable information that allows you to test planning with in-depth analysis of regulatory requirements to ensure product reliability & patient safety. Q1 productions have a Virtual Event Guide & FAQ forum for a better user experience. The mobile app Q1 Events offers all networking experiences of the virtual platform for a seamless experience. For more information about the event, please visit https://ibn.fm/uRrPo.

• XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
• This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
• The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
• XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023

For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy. XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase safety in schools, medical centers and other government services and facilitating rapid airport, border and cruise ship testing to minimize travel risk. Summer is usually the high travel season. With the Covid-19 outbreak, there has been a surge in demand for reliable and rapid testing. XPhyto acknowledges this demand and plans on capitalizing on it with its Covid-ID Lab kit, the fastest PCR system in the world, according to XPhyto’s Chief Executive Officer (“CEO”), Hugh Rogers. “Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes,” said Hugh Rogers, the CEO and director of XPhyto. “We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach,” he added (https://ibn.fm/sgnkA). XPhyto Therapeutics Corp. is a bioscience accelerator focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its profile currently falls under three broad categories: diagnostics, drug delivery, and drug development (https://ibn.fm/GJn0r). For drug development, XPhyto focuses on four late-stage neurology therapeutics within clinical development, along with two other psychedelic medicine programs. For its drug delivery program, XPhyto has a platform technology already in place. It is designed to develop innovative, cost-effective transdermal and oral dissolvable formulations of hybrid-generic, generic and new active pharmaceutical ingredients. XPhyto’s diagnostics lead product is the rapid POC COVID-19 RT-PCR diagnostic test, which launched in Europe in April 2021. The goal for the entire program is to develop real-time ultra-low-cost infectious disease biosensors and making tests, particularly Covid-19 PCR tests, fast and affordable. With the growing requirement for PCR tests for travelling, XPhyto recognizes the tremendous potential for rapid PCR checks from a commercial standpoint. “Rapid, reliable and decentralized PCR tests are exactly what the market needs right now; precisely because incidence rates are falling and therefore sample numbers are decreasing,” noted Michael Kretzer, the CEO of Max Pharma, XPhyto’s distribution partner and pharmaceutical wholesaler (https://ibn.fm/dDOjN). “There will be areas of application where rapid, reliable, and universally recognized results are always required. Accordingly, we see a specialized and sustainable opportunity for the Covid-ID and anticipate a steep order volume uptake in the near future,” he added. Covid-ID Lab represents a significant shift from conventional PCR testing models. Typically, samples collected are shipped to large centralized and automated labs for processing. This has been known to not only take time but also be expensive (https://ibn.fm/4RMhK). XPhyto seeks to address this with its decentralized testing model. It projects that it will yield faster results, more versatile test center options and, most importantly, cost-effectiveness at lower testing volumes. The deployment of the 1000 Covid-ID Lab test kits marks the start of a short trial period for integrating and evaluating XPhyto’s new PCR test system. The entire process is designed so that sample processing will occur directly at the sample collection site. The data collected will allow the company to launch the product successfully in other locations across Europe. XPhyto continues to innovate and grow its three key sectors. With the deployment of its Covid-ID Lab, the company aims at capitalizing on the rapid test market that is projected to reach $39.1 billion by 2023, representing a compound annual growth rate (“CAGR”) of 8.9% between 2021 and 2023. The two other aspects of XPhyto’s diagnostic pipeline include the Peptide biosensor for infectious diseases and the Peptide biosensor for oral health, both of which are still in their design and development stages. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Avricore Health Inc. is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues
• The company’s wholly owned subsidiary, HealthTab, offers fast, accurate and cost-effective point-of-care screening
• Its current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR); HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19
• The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, to offer high quality, low-cost screening tests
• In June 2021, Avricore announced its master agreement to pilot its HealthTab platform for diabetes management in select Shoppers Drug Mart pharmacies
• Avricore’s ultimate aim is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacy

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab(TM) (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. HealthTab HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform. The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (“RWD”) sets and third-party app integration through API. Agreement with Shoppers Drug Mart In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2(TM) analyzers provided by Abbott Rapid Diagnostics. Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes. Near Term Goals Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage. Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies. Market Outlook In 2020, the global point-of-care testing (“POCT”) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (“CAGR”) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19. The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection. Management Team Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion. Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs. David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia. Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia. Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects
• The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities
• Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing
• The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting

The apex of the summer season is a time for movie studios to roll out their most-anticipated productions, TV fans and gamers to pore over lists of new releases and young sun-seekers to enjoy fun business promotions ranging from amusement park activities to themed food events before the looming return to school. As the COVID-19 pandemic continues to occupy headlines worldwide, pharmaceutical companies are working toward announcements of a more sober nature, introducing advances toward potential solutions for the global health crisis as well as other medical concerns lacking such a large level of publicity at this moment in history. Drug bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) recently announced expectations that its R&D program will soon yield reporting on a number of key programs partnering Lexaria’s IP with pandemic-target antivirals, NSAIDs and other products studying hypertension and oral nicotine (https://ibn.fm/Y2SZN). To further the company’s efforts to focus its capital and other resources on Lexaria’s applied research and development programs, the global innovator in drug delivery platforms announced earlier this month that it had chosen to delist its common shares from the Canadian Securities Exchange (CSE ticker LXX) effective July 8, at which point the company’s shares will only trade on the Nasdaq Capital Markets. “Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq, providing more liquidity for shareholders than ever before experienced. The Company expects to realize savings in fees and managerial time and effort that were required to maintain a dual listing,” the announcement states (https://ibn.fm/H4CXz). The announcement adds that securities listed with Nasdaq are designated as a “qualified investment” to maintain Lexaria shares in Canadian Registered Savings Plans, including RRSP, RESP, RRIF, RDSP and TFSA. Lexaria’s DehydraTECH IP is designed to convert drugs into a powdered or liquid form that will make them orally ingestible with quick absorption and efficacy comparable to the bioavailability experienced by inhaling smoked drugs, but without the harmful lung effects smoking can produce. The key R&D programs nearing reporting stage this month are evaluating DehydraTECH’s tolerability and pharmacokinetics (also known as “PK,” or its chemical life cycle from administration to elimination from the body) within animal test subjects; assessing DehydraTECH’s ability to avoid altering the partner drug to such a degree that it would create covalently-bonded new molecular entities (“NMEs”) that would trigger additional regulatory concerns; and, much-anticipated results related to its first human clinical study on utilizing DehydraTECH-processed CBD for purposes of treating hypertension . Lexaria participated in June’s Life Sciences Investor Forum virtual conference series, which facilitates global investor audience interaction with presenting companies. The company’s presentation is now available for on-demand viewing at the conference’s website for a limited time (https://ibn.fm/iwP3Y). Lexaria also recently conducted its annual meeting with investors, and has announced the results of voting on board directors, the company’s auditors, and a pair of proposals related to share issuance and other corporate decisions (https://ibn.fm/vAWvw). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Zero-emissions electric tractor manufacturer Solectrac recently announced that agriculture and construction industry veteran Mani Iyer will succeed the company’s founder as CEO as Solectrac enters an anticipated period of new growth
• Solectrac is a subsidiary of clean energy-focused company Ideanomics Inc., which announced its 100 percent acquisition of the EV tractor manufacturer and distributor last month

The electric vehicle (“EV”) market continues its push toward maturity as many of the world’s governments struggle to enact systemic change to their energy policies as a response to persistent concerns about the global climate (https://ibn.fm/9iw8G). New York-based EV company Ideanomics (NASDAQ: IDEX) is helping to advance clean energy enterprises in response to the established need for solutions. Multinational accounting and professional services network Ernst & Young Global Limited (“EY”) has predicted EVs will become more popular than internal combustion engine (“ICE”) gas-powered vehicles by 2033 in the United States, Europe and China, just over a decade from now, while more conservative forecasts tack another five years onto the timeline but otherwise agree about the ascendance of EVs in the world’s auto industries, according to an analysis published July 6 by InsideEVs (https://ibn.fm/2kBxQ). Ideanomics boosted its stake in Solectrac to 100 percent last month, acknowledging the importance of EV technology not only to transportation but to the agricultural industry as well (https://ibn.fm/450Tb). As such, Solectrac is advancing to a leading position in what is currently a limited field of competition within the specialized EV sector with a product that is fully scalable and able to generate revenue. On July 1, the company announced Solectrac’s new CEO will be agriculture and construction industry veteran Mani Iyer, with expectations that his experience in international equipment sales and marketing, business strategy and development, channel development, supply chain management, product support and service, manufacturing, and quality assurance will help the company build manufacturing and distribution scale for its EV tractor products (https://ibn.fm/Vq5Fb). Iyer is building on a record of delivering distribution and supply chain innovation that has granted him a reputation for proven results within the tractor industry and beyond. “Through a relentless focus on reducing the total cost of ownership, creating a category-leading portfolio of best-in-class tractors and accessories, and driving the buildout of a world-class dealer network, Solectrac will be poised for rapid market share and revenue expansion,” Iyer stated. “We will also leverage lending and financial services from Ideanomics Capital to jumpstart sales through innovative financing and promotions in both our online and dealer channels for a simple and seamless buying experience.” Solectrac’s founder and former CEO Steve Heckeroth led the search for his successor and will continue with the company as chairman of the board, according to the announcement. “Mani brings a wealth of experience in supply chain and channel distribution, along with a stellar network of dealer relationships, all of which will be invaluable to the growth of the company as we continue to lead the zero-emission, regenerative farming movement,” he stated. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• FingerMotion’s subsidiary Xunlian Tianxia Technology entered into an agreement with Happy Life Insurance to create an innovative, data-driven insurance business model
• The model aims to develop new insurance products that can address real consumers’ needs by combining Xunlian’s data mining and customer profiling experience with Happy Life’s insurance expertise
• The new collaboration follows a similar announcement earlier this year in which FingerMotion partnered with Pacific Life Re-Insurance
• FingerMotion expects multiple contracts relating to its insurtech products before the end of calendar 2021

New technologies such as big data, blockchain, the Internet of Things (“IoT”), artificial intelligence (“AI”), and cloud computing have been continuously going mainstream. They have even been integrated into the insurance industry, instigating reforms and making it more effective and widespread. KPMG China’s Head of Insurance Walkman Lee acknowledges that insurtech is reshaping the operational ecosystem, helping to address weaknesses, driving high-quality development, and making insurance available to all (https://ibn.fm/fAh2q). However, implementing programs, which synergistically combine insurance expertise and technological innovations to create integrative value that benefits both the consumer and the insurance companies, has been challenging. This is the problem FingerMotion (OTCQX: FNGR), an evolving technology company, aims to solve through its subsidiary Xunlian Tianxia Technology. Recently, Xunlian Tianxia Technology, a leading cloud service provider in China, and Happy Life Insurance, a life insurance provider in China, entered into an agreement to create an innovative, data-powered insurance business model that will deliver a bevy of digital insurance solutions for customers (https://ibn.fm/1Fn5E). The collaboration will draw from both parties’ expertise and experiences in their respective areas of focus, which, though different, intersect at their reliance on innovative technologies. One of the pioneers in exploring innovative technologies such as blockchain and AI, Xunlian Tianxia Technology has used superior technology to serve an extensive roster of institutional clients and consumers in China. As a result, in addition to amassing abundant customer resources, it has enhanced business efficiency, corporate marketing capabilities, and communication experienced geared towards greater business value creation. The company also has extensive business development experience in big data mining and detailed customer profiling On the other hand, Happy Life Insurance is keen on cultivating an ecosystem that promotes tech-driven enhancements in distribution and operational efficiency while developing customer-focused systems and processes to improve the general insurance experience for customers. The company is also intent on collaborating with partners. As one such partnership, the newly announced collaboration is mutually beneficial. The alliance will combine Happy Life’s understanding of the types of insurance that resonates with consumers and Xunlian’s extensive experience in big data mining and customer profiling. The result will be an integration of big data into insurance products, thus enabling both parties to create and distribute insurance solutions that match consumer profiles, provide increased flexibility, and allow consumers to save costs. Additionally, it is expected to bring about underwriting efficiencies that will trickle down to the companies’ bottom line. “In order to make this collaboration work, we have to dig deep to design insurance products that can address real consumer needs,” commented FingerMotion CEO Martin Shen. “Our teams are uniquely qualified to create new insurance products that push the envelope of what is possible.” In January 2021, FingerMotion announced a landmark agreement with Pacific Life Re-insurance in which it would apply new insights generated from its predictive model to the insurance industry (https://ibn.fm/rAyZI). In what Shen described as an opportunity to create a new business model that augments the insurance value chain and results in more efficiency, the agreement appears to have set the foundation for similar partnerships within the insurance industry. With the company anticipating multiple other contracts relating to its insurtech products before the year’s end, the stage looks set for FingerMotion, its subsidiary, and partners to improve the insurance value chain and create products that can address real consumer needs. Or, more concisely, to push the envelope. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR